Snapshot from Jul 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Santhera expands Biomedica distribution deal
Business distribution agreement

Santhera expands Biomedica distribution deal

Analysis based on 6 articles · First reported Jul 13, 2026 · Last updated Jul 13, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The expanded distribution agreement is expected to increase Santhera's revenue from AGAMREE sales in new markets, though the financial impact is likely modest given the small patient population. The deal reinforces Santhera's international partnership strategy and may support its stock price by demonstrating commercial execution.

Pharmaceuticals Biotechnology
Event Summary

Santhera Pharmaceuticals (SIX: SANN) announced an expansion of its exclusive distribution agreement with Biomedica for AGAMREE (vamorolone), extending the partnership to include Georgia, Kazakhstan, Belarus, Azerbaijan, and Uzbekistan for the treatment of Duchenne muscular dystrophy (DMD) in patients two years and older. Biomedica was originally appointed as a distributor in October 2025. Under the expanded agreement, Biomedica will handle distribution in the five new markets, while Santhera will receive a percentage of net sales. Approximately 2,000 DMD patients live in these countries, where treatment options have been limited to standard corticosteroids. The agreement aims to make AGAMREE available to these patients. Santhera's Chief Commercial Officer Marc Clausse and Biomedica's CEO Oleg Parosin expressed optimism about the partnership.

Entities Involved
stock
Santhera Pharmaceuticals
Santhera expands its distribution network for AGAMREE, potentially increasing revenue and market access in Central Asia and the Caucasus.
Importance 100.0 Sentiment 30.0
priv
Biomedica
Biomedica gains exclusive distribution rights for AGAMREE in five additional countries, strengthening its rare disease portfolio in emerging markets.
Importance 80.0 Sentiment 30.0
cnt
Kazakhstan
Kazakhstan is included in the expanded distribution territory for AGAMREE.
Importance 30.0 Sentiment 20.0
cnt
Georgia (country)
Georgia is one of the five new markets where AGAMREE will be distributed, providing access to DMD patients.
Importance 30.0 Sentiment 20.0
cnt
Belarus
Belarus is one of the new markets for AGAMREE distribution.
Importance 30.0 Sentiment 20.0
cnt
Azerbaijan
Azerbaijan is included in the expanded agreement for AGAMREE.
Importance 30.0 Sentiment 20.0
cnt
Uzbekistan
Uzbekistan is one of the five new markets for AGAMREE distribution.
Importance 30.0 Sentiment 20.0
per
Marc Clausse
As Santhera's Chief Commercial Officer, Clausse announced the expansion, highlighting the company's commitment to global access.
Importance 20.0 Sentiment 0.0
per
Oleg Parosin
As Biomedica's CEO, Parosin expressed enthusiasm for the partnership, leveraging the company's regional infrastructure.
Importance 20.0 Sentiment 0.0
priv
ReveraGen
ReveraGen is the licensor of AGAMREE to Santhera; the expanded distribution does not directly affect ReveraGen.
Importance 10.0 Sentiment 0.0
govactor
International — European Commission
The International — European Commission approved AGAMREE in the EU; not directly involved in this expansion.
Importance 5.0 Sentiment 0.0
govactor
China — National Medical Products Administration
The NMPA approved AGAMREE in China; not directly involved in this expansion.
Importance 5.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The FDA approved AGAMREE in the U.S.; not directly involved in this distribution expansion.
Importance 5.0 Sentiment 0.0
stock
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals holds North American rights to AGAMREE; the expanded distribution does not affect its territory.
Importance 5.0 Sentiment 0.0
priv
Sperogenix Therapeutics
Sperogenix Therapeutics holds rights for China and parts of Southeast Asia; not impacted by this expansion.
Importance 5.0 Sentiment 0.0
+ 5 more entities View on Dashboard
Relationships
Kazakhstan related ↔ Belarus
Kazakhstan related ↔ Uzbekistan
Belarus related ↔ Uzbekistan
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.